Apnimed, Inc. (NASDAQ:APMD)
| Market Cap | 712.44M+11.8% |
| Revenue (ttm) | n/a |
| Net Income | n/a |
| EPS | n/a |
| Shares Out | 39.82M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 41,729 |
| Open | 18.05 |
| Previous Close | 18.04 |
| Day's Range | 17.38 - 18.15 |
| 52-Week Range | 16.00 - 35.29 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | 60.00(+235.38%) |
| Earnings Date | n/a |
Apnimed, Inc. has a live Insider Score.
Scored on 1 qualifying trade from 1 insider in the last 90 days.
About APMD
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$APMD stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in APMD holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by APMD's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
APMD Estimated quarterly lobbying spending
Source: U.S. Senate LDA
APMD Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Gain on reversal of deposit liability | $57.12M | 67.35% |
| Revenue - related party | $12.08M | 14.24% |
| Commercial marketing | $4.83M | 5.69% |
| Oxnimbi | $2.79M | 3.28% |
| Medical affairs | $2.45M | 2.89% |
| Change in fair value long-term debt | $1.66M | 1.96% |
| Cost of services - related party | $1.21M | 1.43% |
| Stock-based compensation | $1.19M | 1.40% |
| Change in fair value of convertible notes | $796.00K | 0.94% |
| Change in fair value of revenue interest liability | $460.00K | 0.54% |
| Connected wearables | $223.00K | 0.26% |
| Other projects | $8.00K | 0.01% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New APMD patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to APMD from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in APMD
| ETF | Est. Holding Size |
|---|---|
| IWMiShares Russell 2000 ETF | $5.64M |
| VTIVanguard Morningstar Total Stock Market ETF | $1.62M |
| IWOiShares Russell 2000 Growth ETF | $1.24M |
| SCHASchwab U.S. Small-Cap ETF | $1.14M |
| IWCiShares Micro-Cap ETF | $695.48K |
| VXFVanguard Extended Market ETF | $604.75K |
Estimated from each fund’s disclosed top holdings × AUM
APMD Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from APMD’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score